More arms, more questions: The new challenge in multispecific drug design
Start here
Multispecific drugs are evolving from bispecifics to trispecifics, T-cell engagers with co-stimulation, NK engagers and dual agonists. Each added binding arm multiplies the number of possible combinations, and the focus of development has shifted from candidate discovery to candidate selection.
Excerpted from BioSpace
Coverage timeline
Follow the coverage to see the different angles.
- BioSpacePickMore arms, more questions: The new challenge in multispecific drug design
Multispecific drugs are evolving from bispecifics to trispecifics, T-cell engagers with co-stimulation, NK engagers and dual agonists. Each added binding arm multiplies the number of possible combinations, and the focus of development has shifted from candidate discovery to candidate selection.
Coverage and heat for this story
Reports so far 1·Heat now 9·Peak heat 10 (Oct 19 13:00)·Reports, 24h +1
Two panels, same clock (pointer stays in sync): top is cumulative editorial reports — only rises; last point = All reports; slope = new reports that hour. Bottom is Live-board heatIndex — 7-day participants with a 24-hour half-life, so it can fall when talk cools.